Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Research

• Publication date

  2013-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-11-2572PMID 24072749PMCID PMC3831658
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer Testes Antigens in Breast Cancer: Biological Role, Regulation, and Therapeutic Applicability

  2012cited by this paper
• Cancer Testis Antigens: A Novel Target in Lung Cancer

  2012cited by this paper
• γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo

  2011cited by this paper
• DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown

  2011cited by this paper
• Photodynamic therapy of cancer: An update

  2011cited by this paper
• The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor Therapy

  2010cited by this paper
• Photodynamic Therapy of Tumors Can Lead to Development of Systemic Antigen-Specific Immune Response

  2010cited by this paper
• Enhanced Systemic Immune Reactivity to a Basal Cell Carcinoma Associated Antigen Following Photodynamic Therapy

  2009cited by this paper
• The functioning antigens: beyond just as the immunological targets

  2009cited by this paper
• Acute phase response induction by cancer treatment with photodynamic therapy

  2008cited by this paper
• Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy.

  2008cited by this paper
• Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy

  2007cited by this paper
• Different lineages of P1A-expressing cancer cells use divergent modes of immune evasion for T-cell adoptive therapy.

  2006cited by this paper
• Photodynamic therapy and anti-tumour immunity

  2006cited by this paper
• Tumor Escape Mutants Develop within an Immune-Privileged Environment in the Absence of T Cell Selection

  2006cited by this paper
• De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.

  2006cited by this paper
• Acute phase response-associated systemic neutrophil mobilization in mice bearing tumors treated by photodynamic therapy.

  2006cited by this paper
• A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy

  2006cited by this paper
• Role of Complement Anaphylatoxin C3a in Photodynamic Therapy-elicited Engagement of Host Neutrophils and Other Immune Cells

  2006cited by this paper
• Deposition of complement proteins on cells treated by photodynamic therapy in vitro.

  2006cited by this paper
• Processing and presentation of tumor antigens and vaccination strategies.

  2006cited by this paper
• Processing and presentation of tumor antigens and vaccination strategies.

  2006cited by this paper
• Immunotherapy for pancreatic cancer — science driving clinical progress

  2005cited by this paper
• Characteristics of complement activation in mice bearing Lewis lung carcinomas treated by photodynamic therapy.

  2005cited by this paper
• Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.

  2005cited by this paper
• Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.

  2004cited by this paper
• Photodynamic therapy for cancer

  2003cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

  2002cited by this paper
• Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors.

  2002cited by this paper
• Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815.

  1999cited by this paper
• T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.

  1999cited by this paper
• The shared tumor‐specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection

  1998cited by this paper
• CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma

  1997cited by this paper
• The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68

  1997cited by this paper
• The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A‐encoded tumor antigen

  1997cited by this paper
• T cell defined tumor antigens.

  1997cited by this paper
• A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

  1996cited by this paper
• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

  1995cited by this paper
• Induction of immune cell infiltration into murine SCCVII tumour by photofrin-based photodynamic therapy.

  1995cited by this paper
• Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815

  1995cited by this paper
• Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.

  1995cited by this paper
• A unique tumor antigen produced by a single amino acid substitution.

  1995cited by this paper
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.

  1995cited by this paper
• A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

  1995cited by this paper
• A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1994influential reference
• Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes

  1994cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Mouse tumor rejection antigens P815A and P815B : Two epitopes carried by a single peptide

  1992cited by this paper
• The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice

  1991cited by this paper
• Photodynamic therapy of cancer.

  1988cited by this paper
• Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression

  1983cited by this paper
• Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. VI. Occasional escape from host rejection due to antigen‐loss secondary variants

  1983cited by this paper

• Pharmacological targeting of nuclear factor (erythroid-derived 2)-like 2 (NRF2): a potential strategy to improve the efficacy of oncological photodynamic therapy.

  2025cites this paper
• Direct and Abscopal Antitumor Responses Elicited by AlPcNE-Mediated Photodynamic Therapy in a Murine Melanoma Model

  2024cites this paper
• Trial watch: an update of clinical advances in photodynamic therapy and its immunoadjuvant properties for cancer treatment

  2023cites this paper
• Drug resistance in glioblastoma: from chemo- to immunotherapy

  2023cites this paper
• Current Challenges and Opportunities of Photodynamic Therapy against Cancer

  2023cites this paper
• Photodynamic therapy improves the clinical efficacy of advanced colorectal cancer and recruits immune cells into the tumor immune microenvironment

  2022cites this paper
• Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells

  2022cites this paper
• Fractional Laser Treatment Boosts Systemic Anti-Tumor Immunity in Combination with OX40 Agonist and PD-1 Blockade

  2021cites this paper
• Substitution effect on carbazole-centered donors for tuning exciplex systems as cohost for highly efficient yellow and red OLEDs

  2021cites this paper
• Photodynamic Therapy in the Treatment of Cancer: A review

  2020cites this paper
• Photodynamic Therapy and Antitumor Immune Response

  2020cites this paper
• Protein 4.1R affects photodynamic therapy for B16 melanoma by regulating the transport of 5-aminolevulinic acid.

  2020cites this paper
• Long-term results of ERCP- or PTCS-directed photodynamic therapy for unresectable hilar cholangiocarcinoma

  2020cites this paper
• Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer.

  2020cites this paper
• Factors Affecting Photodynamic Therapy and Anti-Tumor Immune Response.

  2020cites this paper
• Photodynamic Therapy and Immunity: An Update

  2020cites this paper
• Inhibition of IDO leads to IL-6-dependent systemic inflammation in mice when combined with photodynamic therapy

  2020cites this paper
• Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.

  2019cites this paper
• High-Efficiency Red and Near-Infrared Organic Light-Emitting Diodes Enabled by Pure Organic Fluorescent Emitters and an Exciplex-Forming Cohost.

  2019cites this paper
• Immune Responses after Vascular Photodynamic Therapy with Redaporfin

  2019cites this paper
• Plasma-derived Exosomes Reverse Epithelial-to-Mesenchymal Transition after Photodynamic Therapy of Patients with Head and Neck Cancer

  2018cites this paper
• Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.

  2017cites this paper
• Fractional laser exposure induces neutrophil infiltration (N1 phenotype) into the tumor and stimulates systemic anti-tumor immune response

  2017cites this paper
• Influence of photodynamic therapy on peripheral immune cell populations and cytokine concentrations in head and neck cancer.

  2017cites this paper
• Fractional Laser Releases Tumor-Associated Antigens in Poorly Immunogenic Tumor and Induces Systemic Immunity

  2017cites this paper
• Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions

  2017cites this paper
• Influence of Photodynamic Therapy on the Expression of Cancer/Testis Antigens in Squamous Cell Carcinoma of the Head and Neck.

  2016cites this paper
• Photodynamic Therapy in Veterinary Medicine: From Basics to Clinical Practice

  2016cites this paper
• Development of a novel photosensitizer for photodynamic therapy of cancer

  2016cites this paper
• Acid-Activatable Versatile Micelleplexes for PD-L1 Blockade-Enhanced Cancer Photodynamic Immunotherapy.

  2016cites this paper
• Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model

  2015cites this paper
• Elimination of primary tumours and control of metastasis with rationally designed bacteriochlorin photodynamic therapy regimens.

  2015cites this paper
• Targeting Epigenetic Processes in Photodynamic Therapy-Induced Anticancer Immunity

  2015cites this paper
• Animal models for photodynamic therapy (PDT)

  2015cites this paper
• T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

  2015cites this paper
• Photodynamic Therapy and Antitumor Immune Response

  2015cites this paper
• Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors

  2015cites this paper
• Cancer testis antigens: searching for novel mechanisms of photodynamic therapy-mediated antitumor immune responses.

  2014cites this paper
• Development of photodynamic therapy regimens that control primary tumor growth and inhibit secondary disease

  2014cites this paper
• Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses

  2014cites this paper
• Immune response after photodynamic therapy increases anti-cancer and anti-bacterial effects.

  2014cites this paper
• ER stress, autophagy and immunogenic cell death in photodynamic therapy-induced anti-cancer immune responses

  2014cites this paper
• 5-Aza-2'-deoxycytidine potentiates antitumour immune response induced by photodynamic therapy.

  2014cites this paper
• Photodynamic Therapy and Photobiomodulation: Can All Diseases be Treated with Light?

  2014cites this paper
• Combination Treatment to Target KIT Mutant Cells

  2013cites this paper